Infectious diseases now最新文献

{"title":"Clinical, biological, metabolic, and immune changes associated with the use of sodium-glucose cotransporter 2 inhibitors in people living with HIV","authors":"Vincent Guiraud ,&nbsp;Delphine Sauce ,&nbsp;Randa Bittar ,&nbsp;José Fernandez ,&nbsp;Henri Thévenet ,&nbsp;Elisa Teyssou ,&nbsp;Rana Alkouri ,&nbsp;Dominique Bonnefont-Rousselot ,&nbsp;Anne-Geneviève Marcelin ,&nbsp;Vincent Calvez ,&nbsp;Valérie Pourcher","doi":"10.1016/j.idnow.2025.105040","DOIUrl":"10.1016/j.idnow.2025.105040","url":null,"abstract":"<div><h3>Introduction</h3><div>Positive cardiovascular and renal outcomes associated with the sodium-glucose cotransporter 2 inhibitor (SGLT2i) use are attributed to their anti-inflammatory properties. Persistent immune activation accounts for part of the elevated cardiovascular risk of people living with HIV (PWH), but SGLT2i impact on this population has been poorly described.</div></div><div><h3>Methods</h3><div>All PWH with a history of SGLT2i treatment from May 2020 to April 2023 receiving care at Pitié-Salpêtrière Hospital (Paris, France) and with available pre- and post-treatment blood samples were included. Clinical and biological data were extracted from medical records, metabolic and immune biomarkers from cryopreserved plasma samples.</div></div><div><h3>Results</h3><div>Most of the 20 patients with SGLT2i treatment were men (75 %), with a median [IQR] age of 59 years [55;68], receiving antiretroviral therapy for a median of 21.5 years [15.3;26.5]. Most had type 2 diabetes (95 %), chronic kidney disease (90 %), dyslipidemia (80 %), and hypertension (75 %). SGLT2i treatment was associated with a median weight loss of 3 kg, an increase in hematocrit, and decreased AST levels. LDL, HDL, oxLDL, and Lp-PLA2 levels were unaffected. SGLT2i was associated with inflammasome inhibition and with decreased circulating levels of IL-1β and IL-8. We also observed a decrease in cytokines associated with the recruitment and activation of monocytes-macrophages MCP-1, MIP-1α, MIP-1β, Eotaxin, RANTES, IL-8, and their positive feedback, IL-13/IL-4. Decreased IL-6, CRP, and sCD14 levels were not significant.</div></div><div><h3>Conclusion</h3><div>SGLT2i was associated with weight loss and a significant impact on innate immunity in PWH, with inhibition of inflammasome and monocyte-macrophage activation.</div></div>","PeriodicalId":13539,"journal":{"name":"Infectious diseases now","volume":"55 2","pages":"Article 105040"},"PeriodicalIF":2.9,"publicationDate":"2025-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143440721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Culture yield of 1st and 2nd biopsy in bacterial non-mycobacterial spondylodiscitis in a university hospital","authors":"R Cronier ,&nbsp;F Grados ,&nbsp;J Meynier ,&nbsp;D Michel ,&nbsp;JP Lanoix ,&nbsp;P. Fardellone ,&nbsp;V Goëb","doi":"10.1016/j.idnow.2025.105041","DOIUrl":"10.1016/j.idnow.2025.105041","url":null,"abstract":"<div><h3>Introduction</h3><div>In cases of infectious spondylodiscitis (ISD) where blood cultures are negative, disco-vertebral puncture-biopsy (DVPB) is recommended. In the event of a sterile result, existing literature does not definitively answer the question of whether to initiate empirical antibiotic therapy or to conduct a second DVPB. The aim of this study was to assess the culture yield of DVPB in ISD and to identify the factors associated with a positive DVPB.</div></div><div><h3>Materials and methods</h3><div>A retrospective single-center study was conducted, encompassing all adult patients with ISD having undergone DVPB between 01/01/2009 and 31/10/2021.</div></div><div><h3>Results</h3><div>A total of 177 patients were included. The yield of the first DVPB was 48.6 %. The second DVPB yielded 8.7 % (<em>p</em> &lt; 0.001). Factors significantly associated with the yield of the first DVPB included younger age (<em>p</em> = 0.003), higher CRP levels (<em>p</em> = 0.0496), larger needle size (<em>p</em> = 0.023), and histopathology supporting ISD (<em>p</em> = 0.001), while prior antibiotic therapy (<em>p</em> = 0.001) is a factor associated with negative culture. The second DVPB increased the culture yield by 19.3 %.</div></div><div><h3>Conclusion</h3><div>The yield of the second biopsy is lower than that of the first biopsy but provides an additional diagnostic gain of 19.3%. Antibiotic therapy prior to DVB significantly decreases their yield. The utility of routine post-DVPB blood cultures appears to be limited.</div></div>","PeriodicalId":13539,"journal":{"name":"Infectious diseases now","volume":"55 3","pages":"Article 105041"},"PeriodicalIF":2.9,"publicationDate":"2025-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143440724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of an antimicrobial stewardship program on the appropriate use of carbapenems in a French university hospital (CARBACAI study)","authors":"Julia Santucci ,&nbsp;Guillaume Saint-Lorant ,&nbsp;Aurélie Baldolli ,&nbsp;Christophe Isnard ,&nbsp;Pascal Thibon ,&nbsp;Arnaud de La Blanchardiere","doi":"10.1016/j.idnow.2025.105039","DOIUrl":"10.1016/j.idnow.2025.105039","url":null,"abstract":"<div><h3>Objectives</h3><div>To study compliance with national guidelines for carbapenem (CP) use.</div></div><div><h3>Patients and methods</h3><div>We performed a two-year prospective monocentric and interventional study in a French university hospital. The study was based on three phases (observation (P1), intervention (P2), and post-intervention (P3)) and ended 10 months after intervention. Compliance of CP prescriptions was based on predetermined criteria.</div></div><div><h3>Results</h3><div>Among the 330 prescriptions assessed, treatment adequacy on Day 3 increased from 32.3 % (n = 42/130) during phase P1 to 72.2 % (n = 70/97) during phase P3 (p &lt; 0.01), with a significant impact on indications, dosage, and duration of treatment but not on CP choice. There were no significant changes in overall CP consumption.</div></div><div><h3>Conclusions</h3><div>Implementing an educational antimicrobial stewardship program for hospital CP proper use had a positive impact. Educational reminders are essential to support these improvements.</div></div>","PeriodicalId":13539,"journal":{"name":"Infectious diseases now","volume":"55 2","pages":"Article 105039"},"PeriodicalIF":2.9,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Partner treatment strategies for Chlamydia and Gonorrhea: Time for a reappraisal","authors":"Lea Ben Said ,&nbsp;Anne Conrad ,&nbsp;Sander De Souza ,&nbsp;Dulce Alfaiate ,&nbsp;Florence Ader ,&nbsp;Anne-Sophie Batalla ,&nbsp;Matthieu Godinot","doi":"10.1016/j.idnow.2025.105038","DOIUrl":"10.1016/j.idnow.2025.105038","url":null,"abstract":"<div><h3>Objectives</h3><div>Epidemiological treatment for suspected <em>Chlamydia trachomatis</em> (CT) and <em>Neisseria gonorrhoeae</em> (NG) infections is recommended for exposed partners before laboratory confirmation, within 14 days of exposure to reduce symptoms, break transmission chains, and prevent loss of follow-up. This approach may lead to potential antibiotic overuse by uninfected individuals, thereby enhancing antimicrobial resistance. This study investigated the accuracy of epidemiological treatment for CT and NG.</div></div><div><h3>Patients and Methods</h3><div>Retrospective cross-sectional analysis conducted on asymptomatic exposed partners presumptively treated for CT and/or NG in Lyon’s Sexual Health Clinics between January and December 2023. The positive test rate results of exposed and treated patients were assessed, along with the frequency of potential antibiotic overuse (<em>i.e.</em>, receiving at least one unnecessary antibiotic treatment). The association of potential antibiotic overuse with pre-exposure prophylaxis for HIV, age, gender, sexual orientation, and type of contact was also evaluated.</div></div><div><h3>Results</h3><div>Among 141 patients who received epidemiological treatment, the concordance rate between the test and the reported exposure was 44.8 % for CT and 28.1 % for NG. The proportion of potential antibiotic overuse was 59.6 % (84/141). Potential antibiotic overuse was less common among patients exposed to CT than NG (<em>p =</em> 0.006). Self-identified women (compared with men) and heterosexual (compared with those with other sexual orientations) experienced lower rates of potential antibiotic overuse (<em>p =</em> 0.045 and 0.003, respectively)<em>.</em></div></div><div><h3>Conclusion</h3><div>Given the good follow-up at our clinics, waiting for the laboratory diagnosis before initiation of treatment appears reasonable and would avoid nearly 60% of unnecessary antibiotic treatments in CT and/or NG asymptomatic exposed partners.</div></div>","PeriodicalId":13539,"journal":{"name":"Infectious diseases now","volume":"55 3","pages":"Article 105038"},"PeriodicalIF":2.9,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143414081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on “Delta and Omicron SARS-CoV-2 pneumonia: Comparison of clinical and radiological features”","authors":"Hinpetch Daungsupawong ,&nbsp;Viroj Wiwanitkit","doi":"10.1016/j.idnow.2025.105037","DOIUrl":"10.1016/j.idnow.2025.105037","url":null,"abstract":"","PeriodicalId":13539,"journal":{"name":"Infectious diseases now","volume":"55 2","pages":"Article 105037"},"PeriodicalIF":2.9,"publicationDate":"2025-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143399158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world use, effectiveness, and safety of ceftazidime-avibactam: Results of the French cohort OZAVIE","authors":"Lionel Piroth ,&nbsp;Virginie Vitrat ,&nbsp;Vincent Le Moing ,&nbsp;Philippe Bret ,&nbsp;Yves Brault ,&nbsp;William Greenwood ,&nbsp;Marie-Charlotte Chopin ,&nbsp;Eric Vicaut ,&nbsp;Philippe Montravers ,&nbsp;Pierre Tattevin ,&nbsp;Alexandre Bleibtreu ,&nbsp;on behalf of the OZAVIE research group","doi":"10.1016/j.idnow.2025.105036","DOIUrl":"10.1016/j.idnow.2025.105036","url":null,"abstract":"<div><h3>Background</h3><div>While difficult-to-treat multidrug-resistant Gram-negative bacteria infections increase over time, the real-world effectiveness, use, and safety of ceftazidime-avibactam (CAZ-AVI) for treating hospitalized patients was assessed in 41 French centers.</div></div><div><h3>Procedures</h3><div>OZAVIE was a prospective, multicenter, observational study conducted between March 2019 and November 2021. Hospitalized adult patients having initiated CAZ-AVI for infections within 14 days before enrolment were eligible. Demographic, clinical, microbiological, and therapeutic data were collected. Outcome was categorized as “failure” if the patient died from the initial infection, or if the infections persisted and required another antibiotic or surgery, or if CAZ-AVI was discontinued due to intolerance, and as “global success” otherwise. Patients whose outcome was not “failure”, did not die and required no other antibiotics during the index hospitalization were categorized as “therapeutic success”.</div></div><div><h3>Results</h3><div>257 patients were enrolled: 76 females/181 males, mean age 58.4 years, with diabetes (30.0 %), chronic renal failure (25.7 %), end-stage liver disease (9.3 %) and/or immunocompromised (31.1 %). CAZ-AVI was prescribed for nosocomial pneumonia (34.2 %), complicated urinary tract infections (17.5 %), complicated intra-abdominal infections (14.8 %) and other specified sites (27.6 %). The main pathogens were <em>Pseudomonas aeruginosa</em> (52.4 %), <em>Klebsiella</em> spp. (34.9 %), <em>Enterobacter</em> spp. (18.4 %). Global and therapeutic successes were observed in 79.0 % and 63.4 % of patients, respectively, and 28-day mortality was 20.2 %. Overall, adverse events possibly related to CAZ-AVI were reported in 17.4 % of patients, including serious AEs in 6.2 %.</div></div><div><h3>Conclusions</h3><div>CAZ-AVI is effective and well tolerated for treating various infections – including difficult-to-treat infection sites – and for treating various infections strains, including <em>Pseudomonas aeruginosa</em> and <em>Enterobacter</em> spp.</div></div>","PeriodicalId":13539,"journal":{"name":"Infectious diseases now","volume":"55 2","pages":"Article 105036"},"PeriodicalIF":2.9,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143386680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dalbavancin for prosthetic joint infections: Empirical treatment","authors":"R. Mairesse ,&nbsp;L. Gautie ,&nbsp;M. Merouani ,&nbsp;A. Bouige ,&nbsp;C. Fourcade ,&nbsp;G. Krin ,&nbsp;P. Marlin ,&nbsp;G. Giordano ,&nbsp;S. Baklouti ,&nbsp;P. Gandia ,&nbsp;E. Bonnet","doi":"10.1016/j.idnow.2025.105035","DOIUrl":"10.1016/j.idnow.2025.105035","url":null,"abstract":"<div><h3>Objectives</h3><div>Bone and joint infections are complex and require a long course of antibiotics. Dalbavancin is a long half-life lipoglycopeptide, only indicated for skin and soft tissue infections. Studies on bone and joint diffusion are promising. The objective of this study was to evaluate the efficacy and safety of dalbavancin in combination with piperacillin-tazobactam for intra-operative treatment of knee or hip prosthetic joint infections.</div></div><div><h3>Patients and methods</h3><div>This retrospective and bicentric study was conducted between 2018 and 2022 and included 56 patients. The criteria used to diagnose prosthetic joint infections were those established in 2011 by the MusculoSkeletal Infection Society (MSIS), modified in 2013 at the International Consensus Meeting on Periprosthetic Joint Infections. The efficacy endpoint was the absence of relapse during the two-year follow-up period.</div></div><div><h3>Results</h3><div>Gram-positive cocci infections were the most common. All Gram-positive bacteria were susceptible to dalbavancin. The cure rate at two years was 91.5%. Only four patients experienced treatment failure. Few adverse events were reported, mainly digestive ones (diarrhea and pain).</div></div><div><h3>Conclusion</h3><div>This study provides data outside of the marketing authorization, while respecting the authorized dosage in a population of patients with clearly defined inclusion criteria and a two-year follow-up.</div></div>","PeriodicalId":13539,"journal":{"name":"Infectious diseases now","volume":"55 2","pages":"Article 105035"},"PeriodicalIF":2.9,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143369647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intra-articular procedures and associated septic arthritis: A mini-review","authors":"François Vidal ,&nbsp;Michel Carles ,&nbsp;Johan Courjon","doi":"10.1016/j.idnow.2025.105023","DOIUrl":"10.1016/j.idnow.2025.105023","url":null,"abstract":"<div><div>Native joint septic arthritis (SA) is a severe, potentially life-threatening condition characterized by the invasion of synovial fluid and membrane by pathogens, most commonly bacteria. The rising frequency of intra-articular procedures such as joint aspirations and injections has led to increased concern regarding iatrogenic septic arthritis. This mini-review aims to summarize current understanding of the incidence, risk factors, bacterial etiology, and strategies for preventing SA associated with intra-articular procedures.</div><div>Recent studies report that while iatrogenic SA incidence remains low, ranging between 0.002% and 0.008% following injections, it is higher following arthroscopy (0.14%). Risk factors for iatrogenic SA mirror those of hematogenous SA, comprising older age, male gender, comorbidities such as diabetes mellitus, and systemic corticosteroid therapy. <em>Staphylococcus aureus</em> remains the most frequently implicated pathogen, followed by coagulase-negative staphylococci and streptococci. Preventive measures, including hand antisepsis, patient skin disinfection, and the wearing of surgical masks, are essential to reducing the risk of SA during intra-articular procedures.</div><div>Despite low incidence, SA poses significant morbidity and mortality risks, underscoring the need for adherence to infection control protocols. This review highlights the importance of standardized preventive measures and further research into optimized aseptic techniques, the objective being to mitigate the risk of iatrogenic infections in clinical practice.</div></div>","PeriodicalId":13539,"journal":{"name":"Infectious diseases now","volume":"55 1","pages":"Article 105023"},"PeriodicalIF":2.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142970513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Distribution of beta-lactamase genes in Enterobacteriaceae from human clinical samples","authors":"Md.Kaisar Rahman,&nbsp;Babafela Awosile","doi":"10.1016/j.idnow.2024.105019","DOIUrl":"10.1016/j.idnow.2024.105019","url":null,"abstract":"<div><h3>Background</h3><div>This study aimed to explore the distribution of beta-lactamase genes in Enterobacteriaceae from human clinical samples.</div></div><div><h3>Methods</h3><div>We analyzed data from 83 countries through the Antimicrobial Testing Leadership and Surveillance program, spanning 2004 to 2021. We calculated the proportion of each β-lactamase gene across nine bacterial species and generated a heatmap for β-lactamase genes with a frequency of ≥ 1 % in at least one species.</div></div><div><h3>Results</h3><div>A total of 359 β-lactamase genes were identified, with the highest proportion found in <em>Klebsiella</em> spp. (61.84 %, n = 222), followed by <em>Escherichia<!--> <!-->coli</em> (47.63 %, n = 171), and <em>Proteus</em> spp. (20.61 %, n = 74). The ESBL gene <em>bla</em>_CTX-M−15 was most prevalent in <em>Klebsiella</em> spp. (62.39 %) and <em>E.<!--> <!-->coli</em> (53.16 %). The carbapenemase genes <em>bla</em>_NDM-1, <em>bla</em>_OXA-48, and <em>bla</em>_KPC-2 were notably higher in <em>Providencia</em> spp. (59.47 %), <em>Raoultella</em> spp. (45.45 %), and <em>Serratia</em> spp. (25.24 %), respectively.</div></div><div><h3>Conclusion</h3><div>Further surveillance and research are needed to investigate the diversity of β-lactamase genes across One Health interfaces.</div></div>","PeriodicalId":13539,"journal":{"name":"Infectious diseases now","volume":"55 1","pages":"Article 105019"},"PeriodicalIF":2.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142881424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between in-hospital weight change and 28-day mortality in adults with gram-negative rod bacteremia","authors":"Monika Iwasaki ,&nbsp;Kazuhiro Ishikawa ,&nbsp;Takaaki Isoya ,&nbsp;Emilie Louise Akiko Matsumoto-Takahashi ,&nbsp;Nobuyoshi Mori","doi":"10.1016/j.idnow.2024.105015","DOIUrl":"10.1016/j.idnow.2024.105015","url":null,"abstract":"<div><h3>Background</h3><div>Body weight and fluid balance are critical parameters in the monitoring of patient status, as low body weight and fluid overload are associated with increased mortality in sepsis cases. While body weight reflects nutritional and fluid status, fluid balance is a major indicator of clinical stability. However, limited research has comprehensively evaluated the combined impact of in-hospital weight change and fluid balance on mortality in bacteremia patients, especially those undergoing treatment outside of ICUs.</div></div><div><h3>Aim</h3><div>This study aimed to investigate the association between in-hospital weight change, fluid balance, and 28-day mortality in patients with gram-negative rod (GNR) bacteremia, the objective being to determine the potential usefulness of these parameters in prediction of patient outcomes.</div></div><div><h3>Methods</h3><div>A retrospective cohort study on GNR bacteremia inpatients was conducted from April 2017 to March 2023 at St. Luke’s International Hospital. Univariate analysis, using chi-square and t-tests, was followed by multivariate logistic regression analysis to explore the relationship between 28-day mortality and a number of variables, including in-hospital weight change, with significance level set at p &lt; 0.05.</div></div><div><h3>Results</h3><div>Among 255 patients (230 survivors, 25 non-survivors), mean age was 76.3 years among survivors and 82.4 years among non-survivors (p = 0.05). In the survivor group, 49.1 % were female, compared to 44.0 % of the non-survivors (p = 0.78). In-hospital weight gain was significantly higher in non-survivors (3.81 %) compared to survivors (−0.81 %, p &lt; 0.001). Non-survivors had higher positive daily fluid balance and lower daily total calorie intake (p &lt; 0.05). After adjusting for other variables (age, sex, baseline clinical status and nutritional intake), multivariate analysis showed weight gain to be associated with 28-day mortality (odds ratio 1.10, 95 % CI: 1.01–1.20, p = 0.04).</div></div><div><h3>Conclusion</h3><div>Potentially influenced by fluid overload, in-hospital weight gain is associated with 28-day mortality. As a non-invasive and simple parameter, body weight shows potential as a practical tool for predicting outcomes, especially when accompanied by fluid balance assessments. Further prospective studies are needed to understand the multiple interactions between weight, fluid, and calorie intake.</div></div>","PeriodicalId":13539,"journal":{"name":"Infectious diseases now","volume":"55 1","pages":"Article 105015"},"PeriodicalIF":2.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142846616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}